Publications (original articles or review articles) published in 2016 from OUS - Section of Cardiovascular and Renal Research
10 publications found
Dose requirements of alfentanil to eliminate autonomic responses during rapid-sequence induction with thiopental 4 mg/kg and rocuronium 0.6 mg/kg
J Clin Anesth, 35, 465-474
DOI 10.1016/j.jclinane.2016.09.026, PubMed 27871575
Evaluation of Adherence Should Become an Integral Part of Assessment of Patients With Apparently Treatment-Resistant Hypertension
Hypertension, 68 (2), 297-306
DOI 10.1161/HYPERTENSIONAHA.116.07464, PubMed 27296995
Drug compliance and monitoring of antihypertensive treatment
Tidsskr. Nor. Laegeforen., 136 (10), 920-923
Adherence to medication and drug monitoring in apparent treatment-resistant hypertension
Blood Press, 25 (4), 199-205
DOI 10.3109/08037051.2015.1121706, PubMed 26729283
Association Between Paradoxical HDL Cholesterol Decrease and Risk of Major Adverse Cardiovascular Events in Patients Initiated on Statin Treatment in a Primary Care Setting
Clin Drug Investig, 36 (3), 225-33
DOI 10.1007/s40261-015-0372-9, PubMed 26718960
Tertiary work-up of apparent treatment-resistant hypertension
Blood Press, 25 (5), 312-8
DOI 10.3109/08037051.2016.1172865, PubMed 27124769
Nifedipine GITS/Candesartan Combination Therapy Lowers Blood Pressure Across Different Baseline Systolic and Diastolic Blood Pressure Categories: DISTINCT Study Subanalyses
J Clin Pharmacol, 56 (9), 1120-9
DOI 10.1002/jcph.712, PubMed 26829251
Fixed-dose combination of nifedipine gastrointestinal therapeutic system and candesartan cilexetil in patients with moderate-to-severe essential hypertension: an open-label, long-term safety and efficacy study
J Clin Pharm Ther, 41 (6), 695-702
DOI 10.1111/jcpt.12451, PubMed 27670639
Blood pressure-lowering effects of nifedipine/candesartan combinations in high-risk individuals: subgroup analysis of the DISTINCT randomised trial
J Hum Hypertens, 31 (3), 178-188
DOI 10.1038/jhh.2016.54, PubMed 27511476
Management of the hypertensive patient with elevated heart rate: Statement of the Second Consensus Conference endorsed by the European Society of Hypertension
J Hypertens, 34 (5), 813-21
DOI 10.1097/HJH.0000000000000865, PubMed 26982382